spironolactone has been researched along with Cardiac Death in 2 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "While median time to cardiac death in the spironolactone group was not statistically significantly different than that in the placebo group, adding spironolactone to conventional therapy resulted in reduced occurrence of AF." | 9.51 | Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy. ( Chambers, H; Fonfara, S; Laskary, A; O'Sullivan, ML, 2022) |
| "While median time to cardiac death in the spironolactone group was not statistically significantly different than that in the placebo group, adding spironolactone to conventional therapy resulted in reduced occurrence of AF." | 5.51 | Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy. ( Chambers, H; Fonfara, S; Laskary, A; O'Sullivan, ML, 2022) |
| "cardiac death or death for other causes)." | 1.62 | Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols. ( Bagardi, M; Brambilla, PG; Galizzi, A; Locatelli, C; Malchiodi, D; Zanaboni, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagardi, M | 1 |
| Locatelli, C | 1 |
| Zanaboni, A | 1 |
| Galizzi, A | 1 |
| Malchiodi, D | 1 |
| Brambilla, PG | 1 |
| Laskary, A | 1 |
| Fonfara, S | 1 |
| Chambers, H | 1 |
| O'Sullivan, ML | 1 |
1 trial available for spironolactone and Cardiac Death
| Article | Year |
|---|---|
Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy.
Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Death; Dog Diseases; Dogs; Euthanasia, Animal | 2022 |
1 other study available for spironolactone and Cardiac Death
| Article | Year |
|---|---|
Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cohort Studies; Death; Dog Diseases; Dogs; Female | 2021 |